Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study

被引：0
|
作者：
Cho, B. C. [1 ]
Cheng, Y. [2 ]
Zhou, C. [3 ]
Ohe, Y. [4 ]
Imamura, F. [5 ]
Lin, M-C. [6 ]
Majem, M. [7 ]
Shah, R. [8 ]
Rukazenkov, Y. [9 ]
Todd, A. [10 ]
Markovets, A. [11 ]
Barrett, C. [11 ]
Chmielecki, J. [11 ]
Gray, J. E. [12 ]
Ramalingam, S. S. [13 ]
机构：
[1] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Div Med Oncol,Dept Internal Med, Seoul, South Korea
[2] Jilin Prov Canc Hosp, Dept Oncol, Changchun, Jilin, Peoples R China
[3] Tongji Univ, Pulm Hosp, Dept Oncol, Shanghai, Peoples R China
[4] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan
[5] Osaka Int Canc Inst, Dept Thorac Oncol, Osaka, Japan
[6] Kaohsiung Chang Gung Mem Hosp, Div Pulm & Crit Care Med, Kaohsiung, Taiwan
[7] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain
[8] Maidstone & Tunbridge Wells NHS Trust, Maidstone Hosp, Kent Oncol Ctr, Maidstone, Kent, England
[9] AstraZeneca, GMED Oncol, Global Med Dev, Cambridge, England
[10] AstraZeneca, Biometr & Informat Sci, Cambridge, England
[11] AstraZeneca, IMED Biotech Unit, Translat Sci, Waltham, ME USA
[12] H Lee Moffitt Canc Ctr & Res Inst, Dept Thorac Oncol, Tampa, FL USA
[13] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA8
引用
收藏
页码：177 / 177
页数：1
相关论文
共 50 条
  • [21] Resistance to First-line Osimertinib in EGFR-mutant NSCLC: Tissue is the Issue
    Piotrowska, Zofia
    Hata, Aaron N.
    CLINICAL CANCER RESEARCH, 2020, 26 (11) : 2441 - 2443
  • [22] Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment
    Uchibori, Ken
    Inase, Naohiko
    Nishio, Makoto
    Fujita, Naoya
    Katayama, Ryohei
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (07) : 915 - 925
  • [23] Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA
    Ramalingam, S.
    Reungwetwattana, T.
    Chewaskulyong, B.
    Dechaphunkul, A.
    Lee, K. H.
    Imamura, F.
    Nogami, N.
    Ohe, Y.
    Cheng, Y.
    Cho, B. C.
    Cho, E. K.
    Vansteenkiste, J. F.
    Voon, P. J.
    Zhou, C.
    Gray, J.
    Hodge, R.
    Rukazenkov, Y.
    Soria, J-C.
    ANNALS OF ONCOLOGY, 2017, 28
  • [24] Osimertinib vs Comparator EGFR-TKI As First-Line Treatment for EGFRM Advanced NSCLC (Flaura): Final Overall Survival Analysis
    Reinmuth, Niels
    Bischoff, Helge
    Bohnet, Sabine
    Zum Bueschenfelde, Christian Meyer
    Rueckert, Antje
    Hodge, Rachel
    Rukazenkov, Yuri
    Ramalingam, Suresh S.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 116 - 116
  • [25] Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis
    Ramalingam, S. S.
    Gray, J. E.
    Ohe, Y.
    Cho, B. C.
    Vansteenkiste, J.
    Zhou, C.
    Reungwetwattana, T.
    Cheng, Y.
    Chewaskulyong, B.
    Shah, R.
    Lee, K. H.
    Cheema, P.
    Tiseo, M.
    John, T.
    Lin, M. C.
    Imamura, F.
    Hodge, R.
    Rukazenkov, Y.
    Soria, J-C.
    Planchard, D.
    ANNALS OF ONCOLOGY, 2019, 30 : 914 - +
  • [26] Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis
    Cho, B. C.
    Ohe, Y.
    Zhou, C.
    Reungwetwattana, T.
    Cheng, Y.
    Chewaskulyong, B.
    Lee, K. H.
    Planchard, D.
    Vansteenkiste, J. F.
    Gray, J. E.
    Shah, R.
    Cheema, P. K.
    Tiseo, M.
    John, T.
    Hodge, R.
    Rukazenkov, Y.
    Soria, J-C.
    Lin, M-C.
    Imamura, F.
    Ramalingam, S. S.
    ANNALS OF ONCOLOGY, 2019, 30
  • [27] Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset
    Ohe, Yuichiro
    Imamura, Fumio
    Nogami, Naoyuki
    Okamoto, Isamu
    Kurata, Takayasu
    Kato, Terufumi
    Sugawara, Shunichi
    Ramalingam, Suresh S.
    Uchida, Hirohiko
    Hodge, Rachel
    Vowler, Sarah L.
    Walding, Andrew
    Nakagawa, Kazuhiko
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (01) : 29 - 36
  • [28] Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): final overall survival analysis
    Bischoff, H.
    Bohnet, S.
    Reinmuth, N.
    Rueckert, A.
    zum Buschenfelde, Meyer C.
    Hodge, R.
    Rukazenkov, Y.
    Ramalingam, S. S.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 77 - 77
  • [29] Osimertinib vs SoC EGFR-TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA): Plasma ctDNA Analysis
    Gray, J.
    Okamoto, I.
    Sriuranpong, V.
    Vansteenkiste, J.
    Imamura, F.
    Lee, J. S.
    Pang, Y.
    Cobo, M.
    Kasahara, K.
    Hodge, R.
    Lentrichia, B.
    Dearden, S.
    Ramalingam, S.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1754 - S1755
  • [30] Osimertinib vs. Comparative EGFR TKI as First-Line Therapy in EGFRm advanced NSCLC (FLAURA): Final Overall Survival Analysis
    Bohnet, S.
    zu Bueschenfelde, Meyer C.
    Bischoff, H.
    Reinmuth, N.
    Rueckert, A.
    Hodge, R.
    Rukazenkov, Y.
    Ramalingam, S. S.
    PNEUMOLOGIE, 2020, 74 : S128 - S128
12345